相似文献
1
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia.一名接受慢性淋巴细胞白血病治疗的患者中肾细胞癌对布鲁顿酪氨酸激酶抑制剂依鲁替尼的反应。
Can Urol Assoc J. 2017 May;11(5):E237-E239. doi: 10.5489/cuaj.4316. Epub 2017 May 9.
2
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.布鲁顿酪氨酸激酶抑制剂ONO/GS-4059：从实验台到临床应用
Oncotarget. 2017 Jan 24;8(4):7201-7207. doi: 10.18632/oncotarget.12786.
3
A Rare Instance of Simultaneous Infection with Disseminated Nocardia and Pulmonary Aspergillus in a Patient Receiving Treatment with Ibrutinib for Chronic Lymphocytic Leukemia.1例接受伊布替尼治疗慢性淋巴细胞白血病患者同时发生播散性诺卡菌和肺曲霉菌感染的罕见病例
Cureus. 2018 Oct 8;10(10):e3427. doi: 10.7759/cureus.3427.
4
Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.布鲁顿酪氨酸激酶抑制在慢性淋巴细胞白血病中的作用
Semin Oncol. 2016 Apr;43(2):251-9. doi: 10.1053/j.seminoncol.2016.02.008. Epub 2016 Feb 9.
5
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.依鲁替尼治疗慢性淋巴细胞白血病的药代动力学和药效学评估：低剂量的理论依据。
Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1381-1392. doi: 10.1080/17425255.2016.1239717. Epub 2016 Oct 11.
6
Cytomegalovirus Proctitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: A Case Report.依鲁替尼治疗慢性淋巴细胞白血病患者并发巨细胞病毒性直肠炎：一例报告
Cureus. 2020 Apr 26;12(4):e7837. doi: 10.7759/cureus.7837.
7
Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia.与依鲁替尼治疗慢性淋巴细胞白血病相关的侵袭性曲霉病
Respir Med Case Rep. 2017 Mar 20;21:27-29. doi: 10.1016/j.rmcr.2017.03.011. eCollection 2017.
8
Fulminant Encephalitis in an Ibrutinib-Treated Patient.一位接受依鲁替尼治疗的患者发生暴发性脑炎。
Open Forum Infect Dis. 2020 Jan 20;7(2):ofaa025. doi: 10.1093/ofid/ofaa025. eCollection 2020 Feb.
9
[Small Molecules in the Treatment of Chronic Lymphocytic Leukemia in 2015 and in the Near Future].[2015年及不久的将来用于治疗慢性淋巴细胞白血病的小分子药物]
Klin Onkol. 2015;28 Suppl 3:3S45-9. doi: 10.14735/amko20153s45.
10
Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review.依鲁替尼治疗中枢神经系统复发的套细胞淋巴瘤：一例报告及文献综述
Case Rep Hematol. 2017;2017:9583257. doi: 10.1155/2017/9583257. Epub 2017 Jul 16.
引用本文的文献
1
Exosome-related lncRNA score: A value-based individual treatment strategy for predicting the response to immunotherapy in clear cell renal cell carcinoma.外泌体相关长链非编码 RNA 评分：一种基于价值的个体化治疗策略，用于预测透明细胞肾细胞癌对免疫治疗的反应。
Cancer Med. 2024 Jun;13(11):e7308. doi: 10.1002/cam4.7308.
2
Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.转移性肾细胞癌中对 VEGFR-TKI 和免疫检查点抑制剂耐药的决定因素。
J Exp Clin Cancer Res. 2021 Jun 7;40(1):186. doi: 10.1186/s13046-021-01961-3.
3
Mining Drug-Target Associations in Cancer: Analysis of Gene Expression and Drug Activity Correlations.挖掘癌症中的药物-靶点关联：基因表达与药物活性相关性分析。
Biomolecules. 2020 Apr 25;10(5):667. doi: 10.3390/biom10050667.
4
Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.布鲁顿酪氨酸激酶抑制剂在血液系统恶性肿瘤之外的新适应症
J Clin Med. 2018 Mar 21;7(4):62. doi: 10.3390/jcm7040062.
本文引用的文献
1
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.检查点抑制剂和其他新型免疫疗法治疗晚期肾细胞癌。
Nat Rev Urol. 2016 Jul;13(7):420-31. doi: 10.1038/nrurol.2016.103. Epub 2016 Jun 21.
2
Immune Checkpoint Therapy in Renal Cell Carcinoma.肾细胞癌中的免疫检查点疗法
Cancer J. 2016 Mar-Apr;22(2):92-5. doi: 10.1097/PPO.0000000000000177.
3
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.纳武单抗与依维莫司治疗晚期肾细胞癌的比较
N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
4
Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.依鲁替尼抑制布鲁顿酪氨酸激酶（BTK）和白细胞介素-2诱导的T细胞激酶（ITK）对预防小鼠慢性移植物抗宿主病有效。
PLoS One. 2015 Sep 8;10(9):e0137641. doi: 10.1371/journal.pone.0137641. eCollection 2015.
5
Targets for Ibrutinib Beyond B Cell Malignancies.依鲁替尼在B细胞恶性肿瘤之外的靶点。
Scand J Immunol. 2015 Sep;82(3):208-17. doi: 10.1111/sji.12333.
6
A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.加拿大人对慢性淋巴细胞白血病一线治疗的观点。
Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):303-13. doi: 10.1016/j.clml.2015.03.002. Epub 2015 Mar 26.
7
Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.伊布替尼：用于治疗套细胞淋巴瘤或慢性淋巴细胞白血病患者的综述。
Drugs. 2015 May;75(7):769-76. doi: 10.1007/s40265-015-0380-3.
8
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.布鲁顿酪氨酸激酶（BTK）和白细胞介素-2诱导激酶（ITK）的抑制剂依鲁替尼可增强检查点阻断的治疗性抗肿瘤免疫。
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E966-72. doi: 10.1073/pnas.1500712112. Epub 2015 Feb 17.
9
A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.新型布鲁顿酪氨酸激酶抑制剂依鲁替尼的综述
J Oncol Pharm Pract. 2016 Feb;22(1):92-104. doi: 10.1177/1078155214561281. Epub 2014 Nov 25.
10
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.布鲁顿酪氨酸激酶：从X连锁无丙种球蛋白血症到B细胞恶性肿瘤的靶向治疗
J Clin Oncol. 2014 Jun 10;32(17):1830-9. doi: 10.1200/JCO.2013.53.1046. Epub 2014 Apr 28.
Zotero 插件